Community-based Neuroendocrine Tumor (NET) Research Study
NCT ID: NCT02730104
Last Updated: 2020-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2015-11-23
2020-05-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
NCT02270567
PreOPerative Imaging of NeuroEndocrine Tumors
NCT03958188
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
NCT01423734
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
NCT01673906
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.
NCT06159920
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A: Patients with small bowel NET
Patients with small bowel NET (including appendiceal NETs)
No interventions assigned to this group
Cohort B: Patients with gastric NET
Patients with gastric NET (gastroduodenal)
No interventions assigned to this group
Cohort C: Patients with pancreatic NET
No interventions assigned to this group
Cohort D: Patients with colorectal NET
Patients with colorectal NET (this includes mid-gut)
No interventions assigned to this group
Cohort E: Unknown primary tumor
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with lanreotide depot (Somatostatin Analogue-naïve patients and patients with prior treatment with octreotide long-acting repeatable (LAR) are permitted)
* Radiographically measurable disease
* Has signed the most recent written Patient Informed Consent Form
Exclusion Criteria
* Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors not of lung or thymic origin
* Patients who have previously initiated treatment with lanreotide depot prior to the start of the study cannot have progressed between lanreotide initiation and study entry
* Significant history of uncontrolled cardiac disease (ie, myocardial infarction within 6 months prior to enrollment or has congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Oncology Associates
Sedona, Arizona, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Illinois Cancer Specialists
Arlington Heights, Illinois, United States
Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
Texas Oncology - Beaumont, Mamie McFaddin Ward Cancer Center
Beaumont, Texas, United States
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology - Denton South
Denton, Texas, United States
Texas Oncology
Houston, Texas, United States
Texas Oncology-Tyler
Tyler, Texas, United States
Texas Oncology - Deke Slayton Cancer Center
Webster, Texas, United States
Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncol Ther. 2022 Dec;10(2):463-479. doi: 10.1007/s40487-022-00208-1. Epub 2022 Sep 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-US-52030-340
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.